LigoCyte

Acquired by Takeda
Developing innovative vaccines for the prevention of gastrointestinal diseases.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Bozeman, MT

Initial Investment

2008
Developing innovative vaccines for the prevention of gastrointestinal diseases.

LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.